BRIEF — Pair of allergy treatments made available for Japanese children

Both ALK-Abelló and Stallergenes Greer were able to announce Japanese approval of pediatric use for their house dust mite allergy treatments on Friday.

Stallergenes’ Japanese partner Shionogi (TYO: 4507) received approval for the extension of the indication for Actair, an allergy immunotherapy sublingual tablet for the treatment of house dust mite (HDM) induced allergic rhinitis, to treat patients under the age of 12.

ALK’s partner for Japan, Torii, has gained approval to expand the use of ALK’s HDM sublingual allergy immunotherapy tablet Miticure to include pediatric allergic rhinitis patients.

Both products were approved for adults in 2015.